Desmoplastic infantile ganglioglioma (DIG) and desmoplastic infantile astrocytoma (DIA) are rare, low-grade neuroepithelial neoplasms [1] . BRAF alterations, primarily the V600E mutation and rarely V600D and FXR1-BRAF fusion [3-5, 8, 10, 12] , have been described for DIG/DIA. Although gross total resection is typically curative, tumor location may prevent complete tumor excision. Additionally, tumor recurrence, progression, and rarely leptomeningeal dissemination have been reported [2, 9] , underscoring the need for adjuvant treatment.
With comprehensive molecular analysis, we identified a novel BRAF alteration in a DIG in a 3-month-old female patient who had seizures, apnea, and a right postcontrast enhancing temporal solid multicystic mass (Fig. 1a) . Three months after near-total tumor resection, progressive brainstem leptomeningeal spread (Fig. 1b) prompted a second operation (near-total completion). The tumors from both resections were histologically similar: A prominent desmoplastic stroma had astrocytic, neoplastic neuronal, and poorly differentiated neuroepithelial tumor cell components (Fig. 2) . Mitotic activity (up to 6/10 high-power fields) was limited to the poorly differentiated neuroepithelial component.
Neither necrosis nor microvascular proliferation was observed.
Comprehensive molecular tumor profiling was performed with a 150-gene DNA and an 81-gene RNA neurooncology next-generation sequencing panel (Additional file 1: Methods). A BRAF indel involving codons 600-604 (c.1799_1810delinsACCAAACTGATG; p.V600_W604delinsDQTDG) at low variant allelic frequency (approximately 15%) was the only clinically relevant alteration identified (Additional file 2: Figure S1 ). This alteration was confirmed with Sanger sequencing (Additional file 3: Figure S2 ), and mRNA expression was demonstrated with RNA sequencing (Additional file 4: Figure S3 ). In silico protein modeling (Additional file 1: Methods) with wild-type, pS602, and V600E comparators showed that the novel BRAF indel had the greatest positional change compared with wild-type, which was consistent with stabilization of the kinase-active conformation ( Fig. 3 and Additional file 5: Figure S4) .
Postoperatively, vincristine and carboplatin chemotherapy was initiated upon disease progression. Despite treatment, the leptomeningeal lesions continued to progress (Fig. 1c) , and treatment was switched to BRAF-MEK inhibitors (dabrafenib and trametinib) at 8 months postoperatively. The patient is alive with marked decrease in residual tumor and leptomeningeal disease 14 months after the initial surgery (Fig. 1d) .
Comprehensive tumor molecular profiling led to the discovery of a novel BRAF alteration, increasing the number of BRAF alterations identified in DIG/ DIA. The oncogenic role of this novel BRAF alteration is supported by the protein modeling and by the observed clinical response to BRAF-MEK inhibitors. This finding suggests that, like other low-grade neuroepithelial tumors [6, 7, 11] , mitogen-activated protein kinase (MAPK) pathway activation may have a potential oncogenic-driver role in a subset of patients with DIG/ DIA. After complete DIG/DIA resection, patients typically have a favorable outcome regardless of the histologic features. Dissemination, as in our patient, is exceedingly rare, and no histologic or molecular parameters are currently predictive of a less favorable outcome [1] . Although additional studies are needed, the responsiveness to BRAF-MEK inhibitors in a DIG with a novel, likely oncogenic BRAF alteration suggests that routine molecular testing for this rare pediatric tumor may be part of a personalized medicine approach, particularly when gross total resection is not achieved and adjuvant therapy is considered. 
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